VRT – Morgans rates the stock as Hold

By Broker News | More Articles by Broker News

Recent Medicare data suggests IVF cycle numbers remain solid and Morgans reviews FY16 forecasts, tightening margins slightly to reflect a traditionally weaker period and modestly higher depreciation charges.

FY17 and FY18 estimate are revised down by 1.6% and 0.7% respectively. Morgans retains a Hold rating and raises the target to $6.87 from $6.67.

Sector: Health Care Equipment & Services.

Target price is $6.87.Current Price is $7.19. Difference: ($0.32) – (brackets indicate current price is over target). If VRT meets the Morgans target it will return approximately -5% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →